To see all protocols that comply with the WHO Essential Medicine List 

The tables of drug interactions are not exhaustive, for a more comprehensive list or further detailed information, please refer to product information.

For a complete list of CYP inducers, inhibitors and substrates please see the Cytochrome P450 drug interaction table: http://medicine.iupui.edu/clinpharm/ddis/clinical-table.

Tables adapted from a systematic review using individual product information and the following resources:

Further information on the rationale for limiting tables contents to those interactions deemed clinically relevant:

  • Many chemotherapy regimens contain interacting drugs. In some instances the combinations have been intentionally employed to take advantage of the interaction because of a synergistic effect. In these situations, dosages within a regimen will usually have been adapted to account for the interaction and the interaction may not be listed in the eviQ protocol for this reason.

  • An interaction may not be listed where an interacting drug combination cannot be avoided due to the therapeutic intent of the regimen or the common existence of co-morbidities that require treatment with interacting drugs.

  • Some drugs that have multiple interactions (e.g. clozapine, anti-retrovirals) are rarely used in cancer patients and/or are independently carefully monitored in patients taking them; these may also be omitted from listing in eviQ protocols.

  • In all cases, clinicians are advised that where any drugs with overlapping toxicities are combined, there is a need for close and careful monitoring.

Send feedback for this page


Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/3348

25 May 2019